Pharmacelera, a startup specialising in research into molecules using quantum mechanics and artificial intelligence and a CataloniaBio & HealthTech member, has closed a €1-million round of funding on Capital Cell led by investors from the pharmaceutical sector.

This funding aims to accelerate the company’s commercial plan, especially in the North-American market, and to carry out two proof-of-concept studies in areas that are strategic for the company’s positioning. Recently, the company hired Bill Wiersma, former VP for Sales and Marketing at Labtronics (acquired by PerkinElmer), as its North America Sales Manager.

Pharmacelera has developed the computing platform called PharmScreen® which “helps boost R&D productivity in the health and biomedicine sector by identifying new molecules with the best chance of making it through later stages and becoming a drug,” explains co-founder and CEO Enric Gibert.

The company sells licences (SaaS), yearly subscriptions to its computational technology and chemistry services, and has clients in Europe and the US. 

Photo: from left to right, Oscar Rey, CMO of Pharmacelera, with co-founders Enric Gibert and Enric Herrero - © Pharmacelera

You may also be interested in:

• Pharmacelera gets €1 million through European Horizon EIC Accelerator programme
• Pharmacelera and the Cambridge Crystallographic Data Centre work together on drug discovery